Yes. Controlled trials have documented cognitive improvement in patients treated with HBOT 1 to 5 years after their original brain injury, and case reports extend to decades. The Boussi-Gross 2013 RCT (n=56) specifically enrolled patients 1 to 5 years post-concussion and found significant gains in memory, attention, and executive function after 40 sessions at 1.5 ATA. A 2025 systematic review by Shahid et al. confirmed that HBOT improves neurocognitive function in chronic TBI patients across multiple time intervals from injury. It is one of several HBOT research across brain and neurological conditions currently being explored in clinical research.
The old assumption: after a year, the brain is done healing
Neurological dogma for most of the 20th century held that the adult brain had a fixed recovery window after injury. If function did not return within 6 to 12 months, it was considered permanent loss. This framework was built on structural observations: damaged neurons die, scars form, and the brain reorganizes around the deficit. Recovery beyond the acute phase was attributed to compensation (using uninjured regions to work around damage) rather than true repair.
This model has been thoroughly dismantled by the neuroplasticity research of the past three decades. The brain retains the capacity for structural and functional reorganization throughout life. New synapses form. Existing connections strengthen or weaken based on use. Neurogenesis (new neuron formation) occurs in specific brain regions, including the hippocampus, which is central to memory formation.
The relevance for chronic TBI: if the brain can still change, then an intervention that creates the right conditions for change can produce improvement even years after injury. The question is not whether the brain can recover, but whether the specific pathology in chronic TBI is amenable to the specific mechanism of HBOT.
Why chronic TBI responds to HBOT: the metabolic model
Chronic post-concussion syndrome involves persistent pathology that differs from the acute injury but is equally real. SPECT imaging in chronic PCS patients consistently shows regions of reduced cerebral blood flow that correspond to symptom patterns. These perfusion deficits represent areas where the microvasculature was damaged during the original injury and never fully regenerated.
The tissue in these regions is alive but underperforming. Neurons receive enough oxygen to survive but not enough to function normally. This is sometimes described as a “stunned” or “hibernating” state, borrowing terminology from cardiac medicine. The cells are not dead. They are metabolically compromised.
HBOT at 1.5 ATA addresses this specific pathology through several documented mechanisms:
Angiogenesis: Repeated hyperbaric exposure stimulates the formation of new blood vessels in oxygen-starved tissue. A review of HBOT mechanisms (Biggs et al., 2021) documents increased vascular density in treated tissue. This restores blood supply to regions that have been chronically underperfused since injury.
Reduced neuroinflammation: Chronic neuroinflammation is a hallmark of persistent TBI. Microglia (the brain’s immune cells) remain activated long after the initial injury. HBOT has been shown to modulate microglial activation and reduce inflammatory cytokines in brain tissue.
Stem cell mobilization: Hyperbaric oxygen exposure increases circulating stem cells, including CD34+ cells that migrate to sites of injury. This has been documented in studies by Thom et al. (2006) and represents a mechanism for tissue repair that does not depend on when the original injury occurred.
Mitochondrial repair: Mitochondrial dysfunction persists in chronic TBI and contributes to the metabolic deficit. HBOT upregulates mitochondrial biogenesis and improves oxidative phosphorylation in affected neurons.
None of these mechanisms have a biological expiration date. The question is whether sufficient viable tissue remains to benefit from these processes. In most mild to moderate TBI, the answer appears to be yes, even years later.
Trial evidence for delayed treatment
The Boussi-Gross 2013 study was designed specifically to test whether HBOT could help patients who were long past the natural recovery window. The inclusion criteria required PCS lasting 1 to 5 years. At enrollment, these patients had already gone through the expected recovery period and were left with stable, chronic deficits. The significant improvements documented after 40 HBOT sessions demonstrated that recovery was still possible beyond the traditional window.
The Harch 2020 trial enrolled military veterans with persistent postconcussion symptoms. While the study did not restrict by time since injury, many participants were years post-injury. The positive results in this population further support the delayed-treatment model.
The 2025 systematic review by Shahid et al. in Annals of Medicine and Surgery pooled data from multiple HBOT TBI studies and found consistent neurocognitive improvement across studies that included patients treated at various intervals from injury. The review did not find a clear relationship between time since injury and treatment response, suggesting that the therapeutic window for HBOT in mild TBI may be open-ended.
Case reports extend further. Harch has published case studies of patients treated 10, 15, and even 20+ years after their original brain injury who showed measurable improvement on neurocognitive testing and SPECT imaging after HBOT. These are not controlled data and carry the usual limitations of case reports, but they suggest that the biological capacity for improvement persists for decades.
Protocol for chronic cases
The protocol for treating chronic TBI with HBOT is identical to the standard PCS protocol: 1.5 ATA, 60 minutes at pressure, five sessions per week, 40 to 60 sessions. There is no evidence that patients with longer time since injury require modified parameters.
Some practitioners extend the protocol to 60 or 80 sessions for patients with injuries dating back many years, reasoning that more sessions are needed to reverse deeply entrenched pathology. This is a clinical judgment call, not an evidence-based modification. No trial has compared different session counts stratified by time since injury.
Pre-treatment SPECT imaging can be particularly informative in chronic cases. It identifies which brain regions are hypoperfused and provides a baseline against which to measure treatment response. Post-treatment SPECT typically shows improved perfusion in previously affected regions, providing objective evidence that improvement is occurring at the tissue level. For a deeper look at the protocols used, see our HBOT for brain injury overview.
Managing expectations for chronic TBI
While the evidence supports the possibility of improvement years after brain injury, expectations should be calibrated realistically.
Improvement is not cure. HBOT produces measurable improvement in neurocognitive scores, symptom scales, and brain perfusion. It does not restore the brain to its pre-injury state. Patients who have lived with chronic PCS for years should expect meaningful improvement, not complete resolution.
The response rate is not 100%. Across trials, roughly 60% to 70% of chronic PCS patients show measurable improvement with HBOT. The remaining 30% to 40% show minimal or no benefit. Predictors of response are poorly understood, and there is no reliable way to determine in advance whether a specific patient will respond.
Severity matters. Patients with mild to moderate deficits tend to respond better than those with severe impairment. This makes intuitive sense: the more viable tissue remains, the more potential for recovery. A patient with subtle concentration deficits and mild memory problems has a better prognosis than one with severe executive dysfunction and personality changes.
Comorbidities complicate the picture. Chronic TBI patients often have co-occurring conditions (depression, anxiety, PTSD, sleep disorders, chronic pain) that independently affect cognition. HBOT may improve the TBI component while leaving other contributors unaddressed. Multimodal treatment that addresses all contributing factors typically produces better overall outcomes than HBOT alone.
Gains may require maintenance. Some patients report gradual symptom return months after completing treatment. Whether maintenance sessions (1 to 2 per week) can sustain improvement is an open question with no controlled data. Some practitioners recommend periodic “booster” courses of 10 to 20 sessions. For context on what to expect from HBOT outcomes broadly, see our HBOT success rates page. For the full data supporting TBI treatment, see our HBOT for TBI data review.
The SPECT evidence: seeing chronic improvement on imaging
SPECT brain imaging provides the most compelling visual evidence that HBOT produces real biological changes in chronic TBI. The before-and-after comparisons published in multiple studies show a consistent pattern that is difficult to attribute to placebo effects or expectation bias.
Pre-treatment SPECT in chronic PCS patients typically shows a pattern of regional hypoperfusion. The specific regions affected vary by patient and correlate with their symptom profile. A patient with predominant memory complaints will show temporal lobe hypoperfusion. A patient with executive dysfunction and personality changes will show frontal hypoperfusion. A patient with visuospatial problems will show parietal deficits. These patterns are consistent with the known functional neuroanatomy and provide face validity for the diagnosis.
Post-treatment SPECT, conducted after 40 sessions of HBOT at 1.5 ATA, consistently shows improved perfusion in the previously affected regions. The Boussi-Gross 2013 study published before-and-after SPECT data showing statistically significant increases in cerebral blood flow. The improvements were not uniform (some regions responded more than others) and correlated with the cognitive domains that improved on neurocognitive testing.
This imaging evidence matters for three reasons. First, it demonstrates that HBOT produces measurable tissue-level changes, not just subjective symptom improvement. Second, it provides an objective response biomarker that does not depend on patient effort or reporting bias. Third, it documents that the brain retains the capacity for vascular remodeling (angiogenesis) years after injury, directly challenging the old assumption that chronic deficits are fixed and irreversible.
The main limitation of SPECT evidence is availability. SPECT imaging costs $1,000 to $2,000 per scan, is not covered by insurance for TBI indication, and requires a nuclear medicine facility. Many HBOT clinics do not have SPECT access. Patients who can access SPECT should strongly consider pre-treatment imaging to establish a baseline. Those who cannot access it will need to rely on neurocognitive testing and symptom tracking for response assessment.
How long after injury have improvements been documented?
The formal trial evidence extends to 5 years post-injury (the Boussi-Gross inclusion criteria). But the clinical and case report literature extends much further.
Harch has reported cases of improvement in patients treated more than a decade after their original injury. In one published case, a veteran with blast TBI from the early 2000s showed improved SPECT perfusion and cognitive scores after HBOT administered approximately 15 years post-injury. Another case involved a civilian with a motor vehicle accident TBI from the 1990s who improved with HBOT approximately 20 years later.
These cases are anecdotal and uncontrolled. They do not prove that HBOT works 15 or 20 years after injury with the same reliability as it works 1 to 5 years after. But they demonstrate that the biological window for potential improvement does not close at any known time point. The repair mechanisms that HBOT activates (angiogenesis, neuroinflammation modulation, stem cell mobilization, mitochondrial biogenesis) are not age-limited or time-since-injury-limited. They are fundamental biological processes that persist throughout life.
The practical question for patients considering HBOT many years after injury is not “is it too late?” but rather “is there enough viable tissue to benefit?” In mild to moderate TBI, where the initial injury killed relatively few neurons and the problem is primarily metabolic, the answer appears to be yes regardless of time elapsed. In severe TBI, where significant structural damage occurred, the answer is less certain and depends on individual factors that are difficult to predict without imaging.
Sources
- Boussi-Gross R, Golan H, Fishlev G, et al. “Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury.” PLoS One. 2013;8(11):e79995. DOI: 10.1371/journal.pone.0079995
- Shahid S, et al. “HBOT for neurocognitive deficits following TBI: a systematic review and meta-analysis.” Annals of Medicine and Surgery. 2025. DOI: 10.1097/MS9.0000000000003902
- Harch PG, Andrews SR, Rowe CJ, et al. “Hyperbaric oxygen therapy for mild traumatic brain injury persistent postconcussion syndrome: a randomized controlled trial.” Medical Gas Research. 2020;10(1):8-20. DOI: 10.4103/2045-9912.279978
- Biggs AT, Dainer H, Littlejohn LF. “Effect Sizes for Symptomatic and Cognitive Improvements in Traumatic Brain Injury Following Hyperbaric Oxygen Therapy.” Journal of Applied Physiology. 2021. DOI: 10.1152/japplphysiol.01084.2020
- Thom SR, Bhopale VM, Velazquez OC, et al. “Stem cell mobilization by hyperbaric oxygen.” American Journal of Physiology: Heart and Circulatory Physiology. 2006;290(4):H1378-86. DOI: 10.1152/ajpheart.00646.2005
- Harch PG. “Systematic Review and Dosage Analysis: Hyperbaric Oxygen Therapy Efficacy in Mild Traumatic Brain Injury Persistent Postconcussion Syndrome.” Frontiers in Neurology. 2022;13:815056. DOI: 10.3389/fneur.2022.815056
- Weaver LK, Ziemnik R, Deru K, Russo AA. “A double-blind randomized trial of hyperbaric oxygen for persistent symptoms after brain injury.” Scientific Reports. 2025;15. DOI: 10.1038/s41598-025-86631-6
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
